Physician profile
Patrick Boland
NPI 1083140883
$19,959.16
in general payments reported to CMS, 2019-2025
28 companies · $8,492 in 2025
The $8,492 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $224 · 2023: $269 · 2024: $11K · 2025: $8,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $10K · Consulting Fee: $3,550 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $2,760 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,325.49 |
| Consulting Fee | $3,550.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $2,760.21 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $9,204.65 | 2023-2024 | Monoferric |
| Avyxa Pharma, LLC | $3,279.41 | 2025 | |
| Pfizer INC. | $2,870.83 | 2024-2025 | |
| Beigene USA, INC. | $775.00 | 2022-2024 | Brukinsa |
| Genmab U.S., INC. | $764.19 | 2024-2025 | Epkinly |
| Daiichi Sankyo INC. | $698.31 | 2025 | Vanflyta, Enhertu |
| Astrazeneca Pharmaceuticals Lp | $534.86 | 2024-2025 | Imfinzi, Tagrisso, Enhertu |
| Abbvie INC. | $515.30 | 2022-2025 | |
| Sobi, INC | $200.00 | 2024 | |
| Glaxosmithkline, LLC. | $180.23 | 2023-2025 | Ojjaara, Blenrep |
| Adaptive Biotechnologies Corporation | $162.83 | 2025 | Clonoseq |
| Adc Therapeutics America, INC. | $155.10 | 2025 | |
| Genentech USA, INC. | $150.00 | 2023 | Venclexta |
| Syndax Pharmaceuticals, INC. | $105.40 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.04 | 2024-2025 | Ninlaro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $43.49 | 2024-2025 | Elzonris, Orserdu |
| Janssen Biotech, INC. | $33.70 | 2025 | Erleada |
| Aimmune Therapeutics, INC. | $29.88 | 2025 | Zenpep |
| Caris Mpi, INC. | $27.76 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $22.86 | 2025 | Vyloy |
| Merck Sharp & Dohme LLC | $20.62 | 2025 | Keytruda |
| Rigel Pharmaceuticals, INC. | $19.72 | 2024 | Tavalisse, Rezlidhia |
| Progenics Pharmaceuticals, INC. | $18.44 | 2024 | |
| Coherus Oncology, INC. | $17.78 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $15.08 | 2023 | Imbruvica |
| Eisai INC. | $13.85 | 2024 | |
| Novocure INC. | $13.76 | 2024 | Optune Lua (Novottf-200t) |
| Gilead Sciences, INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Boland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.